Semaglutide and pregnancy do not belong together for routine weight management. For that use, the current Wegovy label calls for treatment to be discontinued when pregnancy is recognized and for a two-month gap before a planned pregnancy. That long window reflects how slowly semaglutide leaves the body.
An accidental early exposure is not proof that harm occurred. Human studies have not found a clear increase in major birth defects so far, but the numbers are too small to establish safety. The timing, reason for treatment and any diabetes care all belong in a prompt review with the prescriber and prenatal clinician.
Semaglutide and pregnancy: what the label says
As of August 2026, the current Wegovy prescribing information says weight loss offers no benefit during pregnancy and may cause fetal harm. It also says the available human pharmacovigilance and clinical-trial data are insufficient to determine a drug-associated risk of birth defects, miscarriage or other maternal or fetal outcomes.
The caution comes partly from animal reproduction studies. In rats, rabbits and monkeys, semaglutide exposure during organ development was associated with embryofetal death, structural abnormalities or altered growth at some exposures relevant to human dosing. Marked maternal weight loss and reduced food intake occurred alongside several of those findings, which makes direct translation to a human pregnancy difficult.
Semaglutide has a half-life of about one week and can remain in circulation for several weeks after the last dose. The label therefore uses at least two months as a preconception clearance window. Our guide to how long semaglutide stays in the system explains that washout in more detail. The two-month buffer is a planning rule; it does not mean that exposure anywhere inside the window proves fetal harm.
What the human pregnancy studies show
The first useful human evidence is cautiously reassuring, but it answers accidental exposure better than intentional use during pregnancy.
A 2024 prospective BMJ Open cohort followed 168 pregnancies with first-trimester exposure to a GLP-1 receptor agonist. Major birth defects occurred in 2.6% of the exposed group, compared with 2.3% in a diabetes reference group and 3.9% in an overweight or obesity reference group. Pregnancy-loss risk was not higher in the adjusted comparisons. The confidence intervals were wide, and the study combined several GLP-1 drugs rather than isolating semaglutide.
A 2024 multinational JAMA Internal Medicine cohort included 938 infants with periconceptional GLP-1 exposure among pregnancies affected by type 2 diabetes. Compared with insulin, the adjusted relative risk for major congenital malformations was 0.95, with a 95% confidence interval from 0.72 to 1.26. That study was also class-wide and primarily evaluated live births, so it cannot settle semaglutide-specific risk.
Semaglutide-specific evidence is smaller. A 2025 Danish cohort found major malformations in 3 of 32 exposed pregnancies, compared with 76 of 547 insulin-exposed pregnancies. The researchers found no statistically significant increase, but most exposed patients had diabetes, many also used insulin, and 32 pregnancies cannot rule out uncommon outcomes. These studies support reassurance after inadvertent early exposure, not a conclusion that semaglutide has been shown safe for use in pregnancy.
An August 2026 U.S. cohort examined different outcomes. Among 429 pregnancy-exposed users with overweight or obesity, the median exposure during pregnancy was 44 days. Compared with nonusers, they had higher adjusted odds of excessive gestational weight gain, gestational diabetes, excessive fetal growth and cesarean delivery. The same outcomes were also elevated among 801 former users, however, and none differed significantly between former and pregnancy-exposed users. The authors interpreted that pattern as more consistent with rebound or underlying risk than with exposure inside pregnancy, but an observational study cannot prove the explanation.
Why “Ozempic babies” is not a fertility indication
Semaglutide is not a fertility medication. The phrase “Ozempic babies” describes unexpected pregnancies reported after GLP-1 treatment, not a clinical indication or a measured effect in a fertility trial.
There is a plausible indirect route. Weight reduction and improved insulin sensitivity can make ovulation more regular in some people with polycystic ovary syndrome. In a small uncontrolled 2023 study of 27 women with PCOS, nearly 80% of those who responded to semaglutide with more than 5% weight loss reported normalized menstrual cycles after six months. The study did not establish that semaglutide improves fertility, but it shows why a previously irregular cycle may become less reliable as contraception.
Semaglutide also differs from tirzepatide on oral contraception. A 43-person pharmacokinetic study found that weekly injectable semaglutide did not reduce exposure to ethinylestradiol or levonorgestrel. The current semaglutide label does not carry tirzepatide’s specific oral-contraceptive precaution. The current Zepbound label advises additional or non-oral contraception for four weeks after treatment begins and after each dose escalation because delayed gastric emptying can affect pill absorption. That warning should not be copied across to semaglutide.
What a prescriber reviews
A positive pregnancy test changes the clinical context, but it does not make a dose date an answer by itself. The reviewing clinicians need the date and amount of the last dose, the product used, estimated gestational age, the reason semaglutide was prescribed, other medications and whether diabetes is present. If semaglutide was part of diabetes care, the plan also has to protect against poorly controlled blood glucose during pregnancy.
Before a new prescription, pregnancy plans, contraception and uncertainty about pregnancy status belong in the intake. A pregnancy test may be requested when status is unclear. At Promise, a licensed provider reviews every request, and not everyone qualifies. The provider also weighs medical history and the known semaglutide side-effect profile, then decides whether any prescription is appropriate.
Semaglutide while breastfeeding
The answer for breastfeeding is not the same as the answer for pregnancy, but the evidence is still thin. The 2026 Wegovy label says there are no data on subcutaneously administered semaglutide or its metabolites in human milk, its effects on a breastfed infant, or its effects on milk production.
One small 2024 milk-transfer study collected samples from eight mothers at 0, 12 and 24 hours after weekly injections ranging from 0.25 to 1 mg. Semaglutide was not detected at the assay’s 1.7 ng/mL detection limit. Their infants were 4 to 23 months old and mixed-fed, so the findings do not answer the same question for a newborn, exclusive breastfeeding, higher doses or long-term development. A clinician has to weigh those gaps against the mother’s indication and feeding goals.
Where compounded semaglutide fits
Pregnancy guidance applies to the semaglutide molecule, not only to a brand name. Promise’s semaglutide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. Compounded semaglutide is prepared for an individual patient on a prescription, but that does not create a separate pregnancy evidence base.
Outside pregnancy, a licensed provider may prescribe a compounded formulation when clinically appropriate; that decision belongs to the patient and doctor. Pregnancy or plans to conceive materially change that clinical judgment, which is why those details are part of the review rather than an afterthought.